Company news
Replimune Group, Inc. news in 2025
Replimune Group, Inc.'s news releases, calls and decks from 2025, newest first.
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
November 6, 2025
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2025
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
October 19, 2025
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
October 18, 2025
Replimune Provides Update Following Type A Meeting with FDA
September 17, 2025
Replimune Announces Type A Meeting Scheduled with FDA
September 1, 2025
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2025
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
July 21, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2025
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 28, 2025
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 21, 2025
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 15, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2025
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 11, 2025
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 20, 2025
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 7, 2025